دورية أكاديمية
Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA
| العنوان: | Outcomes after stereotactic radiosurgery of brain metastases in patients with malignant melanoma and validation of the melanoma molGPA |
|---|---|
| المؤلفون: | Kessel, K. A., Deichl, Andrea, Gempt, J., Meyer, B., Posch, C., Diehl, C., Zimmer, C., Combs, S. E. |
| المصدر: | http://lobid.org/resources/99370670575606441Test#!, 23(10):2020-2029. |
| سنة النشر: | 2021 |
| المجموعة: | Publisso (ZB MED-Publikationsportal Lebenswissenschaften) |
| مصطلحات موضوعية: | Aged, 80 and over [MeSH], Melanoma, Aged [MeSH], Proto-Oncogene Proteins B-raf/genetics [MeSH], GPA, Radiosurgery, Prognostic factors, Radiosurgery/methods [MeSH], Radiosurgery/adverse effects [MeSH], Brain metastases, Melanoma/diagnostic imaging [MeSH], Male [MeSH], Brain Neoplasms/mortality [MeSH], Research Article, Karnofsky Performance Status [MeSH], Female [MeSH], Brain Neoplasms/radiotherapy [MeSH], Follow-Up Studies [MeSH], Mutation [MeSH], Brain Neoplasms/secondary [MeSH], Adult [MeSH], Humans [MeSH], Melanoma/secondary [MeSH], Treatment Outcome [MeSH], Melanoma/radiotherapy [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Melanoma/mortality [MeSH], SRS |
| الوصف: | Introduction!#!Malignant melanoma is the third most common primary in the diagnosis of brain metastases. Stereotactic radiosurgery (SRS) is a well-established treatment option in limited brain disease. We analyzed outcomes of SRS with a particular focus on the graded prognostic assessment (GPA, melanoma molGPA), prognostic factors, and toxicity.!##!Methods!#!We evaluated 173 brain metastases in 83 patients with malignant melanoma. All were treated with SRS median dose of 20 Gy prescribed to the 80 or 100% isodose line between 2002 and 2019. All patients were followed-up regularly, including contrast-enhanced brain imaging as well as clinical examination, initially 6 weeks after treatment, then in quarterly follow-up.!##!Results!#!The median age was 61 years (range 27-80); 36 female and 47 male patients were treated. After a median follow-up of 5.7 months, median OS (overall survival) was 9.7 months 95%-KI 4.7-14.7). LC (local control) at 6 months, 12, 24 months was 89%, 86%, and 72%, respectively (median was not reached). Median DBC (distant brain control) was 8.2 months (95%-KI 4.7-11.7). For OS, a KPS ≥ 80%, a positive BRAF mutation status, a small PTV (planning target volume), the absence of extracranial metastases, as well as a GPA and melanoma molGPA > 2 were prognostic factors. In the MVA, a small PTV and a melanoma molGPA > 2 remained significant.!##!Conclusion!#!The present survival outcomes support the use of the disease-specific melanoma molGPA as reliable prognostic score. Favorable outcomes for SRS compared to other studies were observed. In the treatment of brain metastases of malignant melanoma patients, a multidisciplinary approach consisting of surgery, SRS, chemotherapy, and immunotherapy should be considered. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| ردمك: | 978-9937-0-6705-8 9937-0-6705-7 |
| العلاقة: | https://repository.publisso.de/resource/frl:6445606Test; https://doi.org/10.1007/s12094-021-02607-8Test; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390419Test/ |
| DOI: | 10.1007/s12094-021-02607-8 |
| الإتاحة: | https://doi.org/10.1007/s12094-021-02607-8Test https://repository.publisso.de/resource/frl:6445606Test https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390419Test/ |
| حقوق: | https://creativecommons.org/licenses/by/4.0Test/ |
| رقم الانضمام: | edsbas.94716A94 |
| قاعدة البيانات: | BASE |
| ردمك: | 9789937067058 9937067057 |
|---|---|
| DOI: | 10.1007/s12094-021-02607-8 |